Gibson, in collaboration with NCI and Purdue Research Foundation is developing one or more novel clinical candidate Aza drugs to inhibit the major oncogene.
Gibson Oncology believes we (Gibson, NCI and Purdue Research Foundation) are on the right path to change that story for the benefit of many cancer patients!
Contact us now to learn how we can help your company license and provide lifesaving anti-cancer therapy to the people who need them.
TOUGH ON CANCER, NOT ON PATIENTS. Gibson acquired the Indenos and has worked for several years with experts at the NIH and Purdue University to provide a positive impact on cancer patients’ lives. Firstly, to combat cancer resistance in patients with certain biomarkers, and secondly by achieving high tumor concentrations with less toxicity for children and adults. This has been an evolving field, with Gibson recently acquiring the Azaindenoisoquinolines (Aza’s) which is Gibson’s approach to offering a drug for the ‘undruggable’ problem of cMyc induced cancers. In addition, the FluorIndenos which when combined with antibodies offer targeted antibody warheads as an immunologic approach to cancer therapy.
Gibson oncology is focused on the development and commercialization of first-in-class, best-in-class Aza compounds that selectively bind to and stabilize the G4 quadruplex in the promoter region of the cMyc oncogene to inhibit cMyc expression levels.
More updates to follow…
Read more
http://www.businesswire.com/news/home/20210422005301/en
Read more
https://www.businesswire.com/news/home/20200520005015/en/Gibson-Oncology-Expands-Scientific-Advisory-Board-Oncology
Read more
BRCAness high SLFN11 expression and RB1 loss are highly predictive of response by TNBCs to LMP400 and LMP776. https://stm.sciencemag.org/content/12/531/eaax2625.full
Read more
Indenos are Irreversibly bound to DNA and NOT subject to cancer cell efflux pumps.
Efflux pumping of the Irinotecan out of the cancer cells is associated with both Irinotecan toxicity and with Irinotecan resistance.
The above scan was taken in a patient who became irinotecan refractory during customary chemotherapy, yet shows the shrinkage of metastatic colorectal lesions with only one cycle of therapy.
“I think the next hurdle in precision genomic medicine is figuring out how to circumvent resistance.”
For patients intolerant to severe diarrhea, LMP400 may be a preferred option. In Phase 1 studies, no patients developed Grade III/IV diarrhea.
10% of the US population is homozygous for the UGT allele. Patients with this genetic variant are unable to tolerate usual doses of Irinotecan. Trying to manage their cancers with lower than usual doses decreases progressive free survival (PSF) and may decrease life expectancy for people so afflicted.
Studies show that dogs brought into their veterinarian with lymphomas had 78% response rate for this difficult to treat tumor using the Indenos.
BRCA1- BRCA2-, and PALB2- are synthetic lethal partners of TOP1 inhibition by the Indenos. Indenos synergize with PARP inhibitors in BRCA1- deficient cells.
With the Indeno’s ability to cross the blood brain barrier, there may have enhanced utility for tumors metastatic to the brain.
SLFN11 is a predictive marker of response to the Indenos. These results will guide the phase 2 clinical trials.
“The LMPs are active at nanomolar concentrations, selectively in HR deficient cells, indicative of a synthetic lethality” of the Indenos with HRD genotypes.” This is sensitivity is being explored in phase II studies of solid tumors.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.
Leave a Comment